IMforte: NCT05091567: Phase 3: Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
First Posted 2021-10-25 Trial status Active, not recruiting Sponsor Hoffmann-La Roche Abstract Presentation Meeting Abstract: 2025 ASCO Annual Meeting I May 28, 2025 Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial. Click here for details Peer-reviewed journal publication Efficacy and safety of first-line maintenance t
Dec 31, 2025
MATTERHORN: NCT04592913: Phase 3: Neoadjuvant FLOT +/- Durvalumab Followed by Adjuvant FLOT +/- Durvalumab in GC/GEJC
First Posted 2020-10-19 Trial status Active, not recruiting Sponsor AstraZeneca Abstract Presentation Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC). Meeting Abstract: 2025 ASCO Annual Meeting II Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary June 04, 2025 Click here for det
Dec 31, 2025
TROPION-Breast01: NCT05104866: Phase 3: Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer, treated With 1-2 Prior LOT
First Posted 2021-11-03 Trial status Active, not recruiting Sponsor AstraZeneca Abstract Presentation ESMO 2023 (Annals of Oncology) abstract (LBA11) LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial October 2023 Click here for details AACR 2024 (Cancer Research) abstract (GS02-01) Ab
Dec 15, 2025
KEYNOTE-A18: NCT04221945: Phase 3: Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer
First Posted 2020-01-09 Trial status Active, not recruiting Sponsor Merck Sharp & Dohme LLC Abstract Presentation Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: Final analysis results of the phase 3, randomized, double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 study. Meeting Abstract: 2025 ASCO Annual Meeting II June 04, 2025 Click here for details LBA38 Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervic
Dec 15, 2024
KEYNOTE-A39 : NCT04223856: Phase 3: Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer (EV-302)
First Posted 2020-01-10 Trial status Active, not recruiting Sponsor Astellas Pharma Global Development, Inc. Abstract Presentation Survival Benefit of Enfortumab Vedotin and Pembrolizumab Compared with Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer ESMO - 11 Mar 2024 Click here for details Peer-reviewed journal publication Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer March 6, 2024 - N Engl J
Dec 15, 2023
TOPAZ-1: NCT03875235: Phase 3: Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer
First Posted 2019-03-14 Trial status Active, not recruiting Sponsor AstraZeneca Abstract Presentation A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. 2022 ASCO Gastrointestinal Cancers Symposium Click here for details Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcita
Dec 15, 2022
KEYNOTE-522: NCT03036488: Phase 3: Study of Pembrolizumab (MK-3475) Plus Chemo vs Placebo Plus Chemo as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy
First Posted 2017-01-30 Trial status Completed Sponsor Merck Sharp & Dohme LLC Abstract Presentation 2019 San Antonio Breast Cancer Symposium. Abstract GS3-03. Presented December 12, 2019. Schmid P, Park YH, Ferreira M, et al: KEYNOTE-522: Phase 3 study of neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy, followed by adjuvant pembrolizumab versus placebo for early triple-negative breast cancer: Pathologic complete response in key subgroups and by treatm
Dec 15, 2021
KEYNOTE - 826: NCT03635567: Phase 3: Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy First line Cervical cancer
First Posted 2018-08-17 Trial status Completed Sponsor Merck Sharp & Dohme LLC Abstract Presentation KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer. June 3, 2023 2023 ASCO Annual Meeting Click here for details Peer-reviewed journal publication Pembrolizumab for Persistent, Recurrent, or Metastati
Dec 15, 2021
HER2CLIMB: NCT02614794: Phase 3: Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer
First Posted 2015-11-25 Trial status Completed Sponsor Seagen Inc. Abstract Presentation Phase III HER2CLIMB Trial Yields Positive Data in Patients With HER2-Positive Metastatic Breast Cancer and Brain Metastasis Late-breaking oral presentation, San Antonio Breast Cancer Symposium 2019; results subsequently published in NEJM (2020). Click here for details Peer-reviewed journal publication Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer Dece
Dec 15, 2020